<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04056169</url>
  </required_header>
  <id_info>
    <org_study_id>seeCAP</org_study_id>
    <nct_id>NCT04056169</nct_id>
  </id_info>
  <brief_title>Comparison of High-dose Rosuvastatin Versus Low-dose Rosuvastatin Plus Ezetimibe on Carotid Plaque Inflammation in Patients With Acute Coronary Syndrome</brief_title>
  <official_title>Comparison of High-dose Rosuvastatin Versus Low-dose Rosuvastatin Plus Ezetimibe on Carotid Plaque Inflammation in Patients With Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Combination therapy of ezetimibe with a low-dose statin is occasionally used to avoid
      statin-related side effects in clinical practice among patients with atherosclerotic
      cardiovascular disease. This approach is equivalent to high-dose statin therapy to decrease
      LDL cholesterol level by &gt;50%, allowing such patients to achieve LDL cholesterol target.
      However, it remains uncertain whether combination therapy with ezetimibe and low-dose statin
      verse high-dose statin monotherapy similarily suppress atherosclerotic plaque inflammation.
      This study is to compare high-dose rosuvastatin versus low-dose rosuvastatin plus ezetimibe
      on carotid plaque inflammation in patients with acute coronary syndrome using
      18F-fluorodeoxyglucose (18FDG) positron emission tomography (PET) imaging.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 29, 2017</start_date>
  <completion_date type="Actual">July 23, 2019</completion_date>
  <primary_completion_date type="Actual">July 23, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in most-diseased segment (MDS)-tissue blood ratio (TBR) of the index vessel</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in MDS TBR</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in whole vessel TBR within the index vessel</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in whole vessel TBR of the aorta</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total cholesterol</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in triglyceride</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HDL-cholesterol</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LDL-cholesterol</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in high sensitive C-reactive protein</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Carotid Atherosclerotic Plaque With Inflammation</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>rosuvastatin 20 mg once a day for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ezetimibe/rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ezetimibe/rosuvastatin 10/5 mg once a day for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high-dose rosuvastatin</intervention_name>
    <description>rosuvastatin 20 mg once a day for 6 months</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low-dose rosuvastatin plus ezetimibe</intervention_name>
    <description>ezetimibe/rosuvastatin 10/5 mg once a day for 6 months</description>
    <arm_group_label>ezetimibe/rosuvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. aged ≥ 19 years

          2. acute coronary syndrome, carotid artery disease (diameter stenosis 20-50%), and at
             least one 18FDG uptake lesion in the carotid artery (target to background ratio (TBR)
             ≥ 1.6) by 18FDG PET/CT imaging

          3. written consent

        Exclusion Criteria:

          1. previous history of carotid endarterectomy or stenting

          2. schedule for cardiac or major surgery within the next 6 months

          3. statin or ezetimibe therapy in the past 4 weeks

          4. chronic disease needed to be treated with oral, intravenous, or intraarticular steroid

          5. end-stage renal disease

          6. chronic liver disease

          7. history of cancers within the past 3 years

          8. pregnant, breast-feeding or child-bearing potential

          9. expected life expectancy within 2 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 8, 2019</study_first_submitted>
  <study_first_submitted_qc>August 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2019</study_first_posted>
  <last_update_submitted>August 13, 2019</last_update_submitted>
  <last_update_submitted_qc>August 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rosuvastatin</keyword>
  <keyword>ezetimibe/rosuvastatin</keyword>
  <keyword>carotid plaque inflammation</keyword>
  <keyword>fluorodeoxyglucose F18</keyword>
  <keyword>positron emission tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Plaque, Atherosclerotic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

